Depleting CD8 + T cells compromised the survival outcomes of the combination treatment and distinctly abrogated its effect on tumor growth (Figs. 4E, F, and S4B), emphasizing the essential contribution of CD8 + T cells to the effectiveness of the combination therapy. The gene discussed is CD8A; the disease is neoplasm.